CXCR2 and asthma: This selective CXCR2 antagonist was used in a trial to treat patients with severe asthma, but it was not effective in controlling disease deterioration.[59] The participants in this experiment did not smoke, as smoke exposure can lead to upregulation of CXCL8 levels in the airway mucosa, exacerbating neutrophil recruitment and NET formation.